Clinical utility of open lung biopsy for undiagnosed pulmonary infiltrates

doi:10.1016/S0002-9610(05)80364-2

The American Journal of Surgery

Volume 164, Issue 2, August 1992, Pages 104-107

https://doi.org/10.1016/S0002-9610(05)80364-2 Get rights and content

Open lung biopsy (OLB) is often performed as the definitive diagnostic procedure in patients with undiagnosed pulmonary infiltrates, but controversy exists as to the clinical utility of this practice. A retrospective review of 50 consecutive patients who underwent OLB for undiagnosed pulmonary infiltrates was done to assess the diagnostic value as well as the frequency with which these results affected therapy and mortality. Histologic tissue diagnoses were obtained in all patients. Specific pathologic diagnoses were obtained in 56% of patients, nonspecific in 44%. Lobar or lateralized infiltrates were more likely to yield a specific diagnosis (87%) than diffuse, bilateral infiltrates (42%). Thirty-four patients (68%) had previously had a nondiagnostic transbronchial biopsy; 58% of these patients had a specific diagnosis established by OLB. Twelve patients (24%) were in acute respiratory failure at the time of OLB; this group had a 50% mortality rate as compared with only 2.6% for patients not in acute respiratory failure (p<0.01). Therapy was altered (new specific or nonspecific treatment initiated or therapy withdrawn) in 78% of patients undergoing OLB. Thirty-day in-hospital survival was significantly higher in patients for whom either specific or nonspecific therapy was indicated and initiated versus those in whom no therapy was initiated or all therapy was withdrawn (mortality: 5.5% versus 35.7%; p=0.01). Mortality was not related to the presence of immunosuppression or to the finding of a specific diagnosis. The overall mortality rate of 14% in this series compares favorably with mortality rates found in similar series, reflecting differences in patient populations and possibly the timing of intervention. OLB remains a clinically valuable diagnostic tool in selected patients.

References (14)

GreenmanRL et al.
Lung biopsy in immuno-compromised hosts
Am J Med
(1975)
PenningtonJE et al.
Pulmonary infiltrates in patients with hematologic malignancy: assessment of transbronchial biopsy
Am J Med
(1977)
FitzgeraldW et al.
The role of open lung biopsy in patients with the acquired immunodeficiency syndrome
Chest
(1987)
CrawfordSW et al.
Open lung biopsy diagnosis of diffuse pulmonary infiltrates after marrow transplantation
Chest
(1988)
RubinRH et al.
Infection in the renal transplant patient
Am J Med
(1981)
RossiterSJ et al.
Open lung biopsy in the immunosuppressed patient: is it really beneficial?
J Thorac Cardiovasc Surg
(1979)
ChuangMT et al.
Bronchoscopy in diffuse lung disease: evaluation by open lung biopsy in nondiagnostic transbronchial lung biopsy
Ann Otol Rhinol Laryngol
(1987)

There are more references available in the full text version of this article.

Cited by (36)

Which patients with ARDS benefit from lung biopsy ?
2015, Chest
A central tenet of caring for patients with ARDS is to treat the underlying cause, be it sepsis, pneumonia, or removal of an offending toxin. Identifying the risk factor for ARDS has even been proposed as essential to diagnosing ARDS. Not infrequently, however, the precipitant for acute hypoxemic respiratory failure is unclear, and this raises the question of whether a histologic lung diagnosis would benefit the patient. In this review, we consider the historic role of pathology in establishing a diagnosis of ARDS and the published experience of surgical and transbronchial lung biopsy in patients with ARDS. We reflect on which pathologic diagnoses influence treatment and suggest a patient-centric approach to weigh the risks and benefits of a lung biopsy for critically ill patients who may have ARDS.
Surgical lung biopsy in adult respiratory distress syndrome: A meta-analysis
2014, Annals of Thoracic Surgery
Adult respiratory distress syndrome (ARDS) has a high mortality rate and consumes considerable health care resources. It is not clear whether specimens obtained from open lung biopsy (OLB) in ARDS provide a specific diagnosis, alter therapy, or affect outcome. This meta-analysis attempts to determine whether OLB is safe, provides a specific diagnosis, changes therapy, or affects survival.
A computerized search was performed of Medline and PubMed from January 1988 to December 2012 of English language studies of acute respiratory failure and diffuse pulmonary infiltrates that evaluated OLB in primarily adult mechanically ventilated patients. Of 194 abstracts retrieved, 64 articles were reviewed; 130 articles were excluded because they did not evaluate OLB. After applying the selection criteria, 24 articles were included.
OLB in ARDS provided a specific diagnosis in 84% of patients and altered management in 73%. Hospital mortality was 43%. The complication rate for OLB in ARDS was 22%, but death from OLB was rare.
OLB in ARDS is a potentially productive procedure that provides a specific diagnosis and leads to a change in management in high proportions of patients. ARDS has a high mortality rate, which OLB does not appear to increase. Owing to a lack of randomized controlled trials, a survival advantage of OLB in ARDS could not be demonstrated.
Role of Lung Biopsy in Diffuse Lung Disease
2010, Medical Management of the Thoracic Surgery Patient
Role of Lung Biopsy in Diffuse Lung Disease
2009, Medical Management of the Thoracic Surgery Patient
Acute exacerbation of idiopathic pulmonary fibrosis: A systematic review
2008, European Journal of Internal Medicine
Citation Excerpt :
It can not only suggest a specific diagnosis but can also help in prognostication [30]. Moreover, a surgical lung biopsy can lead to a change in the original diagnosis in about 50–70% of the patients [30–32] and can be safely performed even in the mechanically ventilated patient [32]. Numerous studies have performed surgical lung biopsy in AE-IPF and have documented the presence of diffuse alveolar damage on a background of usual interstitial pneumonia [12, 26, 27, 33, 34].
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a clinical entity defined by rapid deterioration of IPF during the course of the disease that is not due to infections, pulmonary embolism, or heart failure. The condition needs to be differentiated from acute interstitial pneumonia (or Hamman–Rich syndrome), which occurs in patients with no underlying lung disease. The exact etiology and pathogenesis remain unknown, but the condition is characterized by diffuse alveolar damage (on a background of IPF) that probably occurs as a result of a massive lung injury due to some unknown etiologic agent. High-resolution computed tomography can help in prognostication and management of this condition. Once infections and other causes of worsening have been excluded, treatment involves enhanced immunosuppression with pulse doses of methylprednisolone and cytotoxic agents. Our systematic review shows that the outcome, however, is poor, with 1-month and 3-month mortality around 60% and 67%, respectively. Few studies have shown beneficial effects of cyclosporine, pirfenidone, and anticoagulants in the management and prevention of AE-IPF. The etiology, risk factors, pathogenesis, therapy, prognosis, and predictors need to be studied and the potential role of newer agents in the management and prevention of AE-IPF needs to be further clarified.
Value of open lung biopsy in immunocompromised children
2000, Journal of Pediatrics
Citation Excerpt :
Death occurred only in patients with ARD, and the overall mortality rate in this group did not differ between patients receiving ventilatory support and those not receiving ventilatory support. As in previous studies, the overall mortality rate was similar for patients with and without specific diagnosis by OLB.29,30 However, the mortality rate within the first 30 days after surgery was significantly higher in the ventilated group than in the non-ventilated group.
Objectives: To determine the value of open lung biopsy (OLB) in terms of diagnosis, morbidity, mortality, and benefits in immunocompromised children with pulmonary involvement. Study design: We retrospectively reviewed 36 OLBs performed in 32 immunocompromised children between 1985 and 1998. Seventeen biopsies were performed in patients with primary immunodeficiency syndromes and 19 in patients with secondary immunodeficiency syndromes. Twenty-eight biopsies were performed because of a lack of response to ongoing antimicrobial treatments with negative or positive findings on bronchoalveolar lavage (BAL) and a deteriorating clinical or radiologic course, and 8 biopsies were performed because of persistent chest x-ray infiltrates. Results: Diffuse pulmonary infiltrates were observed on chest x-ray in 28 cases, hyperinflation in 3 cases, and nodular infiltrates in 5 cases. A histopathologic diagnosis was possible for all 36 OLBs. Specific diagnosis was obtained in 22 (61%) (12 infectious agents, 6 tumors, 4 bronchiolitis obliterans) and non-specific diagnosis in 14 (39%). Fungi were the main infectious agents (8 of 12). For the diagnosed infections, BAL provided 4 true-positive, 3 false-positive, and 6 false-negative results. Specific treatment was changed in 77% of cases, providing real benefits in 12 (33%) cases. The morbidity and overall mortality rates were 31% and 33%, respectively. The mortality rate was significantly higher in the first 30 days after OLB in patients receiving ventilatory assistance (58%). Conclusions: OLB in immunocompromised children with deteriorating clinical or radiologic course is a sensitive diagnostic tool. (J Pediatr 2000;137:165-71)

View all citing articles on Scopus

¹: From the Department of Surgery (JDW), University of Washington School of Medicine, and Wenatchee Valley Clinic (CS, SK, MB, BK), Seattle, Washington.

View full text

Clinical utility of open lung biopsy for undiagnosed pulmonary infiltrates

Am J Med

Am J Med

Chest

Chest

Am J Med

J Thorac Cardiovasc Surg

Bronchoscopy in diffuse lung disease: evaluation by open lung biopsy in nondiagnostic transbronchial lung biopsy

Ann Otol Rhinol Laryngol